Relive the sights and memorable moments from San Antonio in the #SABCS25 Photo Gallery. View now in SABCS Meeting News:
buff.ly/zrdns5H

#SABCS25 session recordings are available to meeting registrants for on-demand viewing through Tuesday, March 31. Learn more:
buff.ly/Uc3UCkZ

The final General Session at #SABCS25 featured supportive interventions for survivors, menopausal hormone therapy risk analysis, and more. Learn more in SABCS Meeting News:
buff.ly/dkUM48A

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more:
buff.ly/Z5orepv

The View from the Trenches session that closed out #SABCS25 provided clinical context for the cutting-edge data presented from across the continuum of breast cancer research. Read a recap in SABCS Meeting News:
buff.ly/p5WGxsF

During her award lecture at #SABCS25, @AACR Outstanding Investigator Awardee Sara Tolaney emphasized the importance of always putting patients first. Learn more in SABCS Meeting News:
buff.ly/umygAOs

#SABCS25 session recordings are available to meeting registrants for on-demand viewing through Tuesday, March 31. Learn more:
buff.ly/Uc3UCkZ

Partnership in Progress: Panelists at #SABCS25 discussed the vital role of patient advocacy in advancing breast cancer research, policy, and care. Learn more in SABCS Meeting News:
buff.ly/8gTmK7p

2025 William L. McGuire Memorial Lecture Award recipient Armando E. Giuliano, MD, reflected on successes and setbacks related to his career-defining studies at #SABCS25. Learn more in SABCS Meeting News:
buff.ly/gVgMCBC

#SABCS25 session recordings are available to meeting registrants for on-demand viewing through Tuesday, March 31. Learn more:
buff.ly/Uc3UCkZ

Experts revealed findings from de-escalation trials, preoperative radiotherapy study, and more during the second General Session at #SABCS25. Learn more in SABCS Meeting News:
buff.ly/ao6GGJC

The inaugural SABCS Salutes Patients and Survivors event at #SABCS25 emphasized the importance of empowering this vital community. Learn more in SABCS Meeting News:
buff.ly/qxJSLN9

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more:
buff.ly/Z5orepv

Experts reported potentially practice-changing findings, including data from lidERA and HER2CLIMB-05 trials, during the first General Session at #SABCS25. Learn more in SABCS Meeting News
buff.ly/dkUM48A

#SABCS25 recap: Joan Brugge, PhD, shared new insights into breast tumorigenesis in BRCA1/2-mutation carriers. Learn more in SABCS Meeting News:
buff.ly/8BJVpIA

#SABCS25 session recordings are available to meeting registrants for on-demand viewing through Tuesday, March 31. Learn more:
buff.ly/Uc3UCkZ

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more:
buff.ly/Z5orepv

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more:
buff.ly/Z5orepv

#SABCS25 e-posters are available to meeting registrants for viewing through Tuesday, March 31. Learn more:
buff.ly/Z5orepv

#SABCS25 recap: Panelists examined the latest knowledge about the connections between breast cancer and lifestyle factors. Learn more in SABCS Meeting News:
buff.ly/zFi38MB

#SABCSSnippets: Marcela Mazo talked with Marjolein Smidt at #SABCS25 about the results of the Phase III BOOG 2013-08 trial, which indicate that sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer.
buff.ly/MrXAKvF

#SABCSSnippets: Saba Shaikh talked with Sonia Pernas at #SABCS25 about the Phase II SUMIT-BC trial, which showed that the CDK7 inhibitor samuraciclib + fulvestrant showed efficacy in HR+ metastatic breast cancer patients previously treated with a CDK4/6 inhibitor. buff.ly/gkjdRPf

Ruth O'Regan summarizes the 2025 FDA approvals for HR+ metastatic breast cancer, including datopotamab deruxtecan, trastuzumab deruxtecan, and imlunestrant. Watch now in the Best of #SABCS25:
buff.ly/vDfAHmH

#SABCSSnippets: Rahul Gosain of the Oncology Brothers talked with Marleen Kok at #SABCS25 about how lobular carcinoma—which comprises 10-15% of all invasive breast cancers—differs from ductal carcinoma.
buff.ly/r4mA3Vx @marleenkok.bsky.social @oncbrothers.bsky.social

Hope Rugo reviews biomarker subgroup results from the evERA phase III trial, updated EMBER-3 efficacy of imlunestrant in advanced breast cancer, and WISDOM 1.0 findings on risk-based screening. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH @hoperugo.bsky.social

Hope Rugo shares the first positive results for an oral SERD (giredestrant) in the adjuvant setting and key findings from the phase III lidERA trial in ER+, HER2− early breast cancer. Watch now in the Best of #SABCS25:
https//buff.ly/fUHtwnq @hoperugo.bsky.social

#SABCSSnippets at #SABCS25: Julie Nangia and @ErikaHamilton9 discussed HER2CLIMB-05, which showed that adding tucatinib to 1st-line maintenance therapy with trastuzumab and pertuzumab delayed progression in patients with HER2+ metastatic breast cancer.
buff.ly/YIwYQEh @erikahamilton9.bsky.social

Janice Tsang reviews a year in metastatic breast cancer, highlighting key trial updates in TNBC, HER2+ and HR+/HER2− disease—including ASCENT, DESTINY-Breast, HER2CLIMB, EMBER-3 and SERENA-6. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH

William Gradishar reviews key #SABCS25 findings in early breast cancer, including neoadjuvant trials TBCRC056 and OlympiA exploring PARP inhibitors and immunotherapy in BRCA-mutated disease. Watch now in the Best of SABCS®:
buff.ly/vDfAHmH

#SABCSSnippets: Virginia Kaklamani talked with Hope Rugo at #SABCS25 about the field of endocrine therapy, including data from the Phase III evERA Breast Cancer Study and from the Phase II ELEVATE Study.
buff.ly/Bw3mSWW @vkaklamani.bsky.social @hoperugo.bsky.social